Chronic Lymphocytic Leukemia

Welcome to the Chronic Lymphocytic Leukemia Resource Center! Take a look around and find current information, news, literature, and other resources from this area of oncology treatment. We hope this site is helpful to your practice. If you have any feedback or questions, please contact jadpro-editor@conexiant.com.

Amber Koehler, PA-C
Mayo Clinic
Rochester, Minnesota

Chronic Lymphocytic Leukemia Resource Center

Interview with Lisa Nodzon, PhD, APRN, AOCNP: Expert Perspectives on Richter Transformation

Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab

CLL Society - Treatment Decision Tool

MURANO Trial - Blood

Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma Version 2.2023

Leukemia & Lymphoma

Richter transformation - retrospective treatment outcomes analysis in Polish Adult Leukemia Study Group

Blood

Minimal residual disease-driven treatment intensification with sequential addition of ibrutinib to venetoclax in R/R CLL

American Journal of Hematology

Impact of targeted agents on survival of chronic lymphocytic leukemia patients age >65 relative to age- and sex-matched population

Nature Medicine

Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial

New England Journal of Medicine

Chronic lymphocytic leukemia therapy guided by measurable residual disease

Blood Advances

Results of VOICE: A global survey of disease-specific knowledge and perspectives of real-world patients with CLL

Oncology

Fixed-duration ibrutinib-venetoclax vs chlorambucil-obinutuzumab for previously untreated CLL

Journal of Clinical Oncology

Importance of low- and moderate-grade adverse events in patients' treatment experience and treatment discontinuation: An analysis of the E1912 Trial

JACC: CardioOncology

Cardiovascular Toxicities of BTK Inhibitors in Chronic Lymphocytic Leukemia

FDA Press Release

FDA granted accelerated approval to pirtobrutinib for CLL and SLL

“Double-Refractory” CLL: Progressive Disease after Therapy With Both a BTK Inhibitor and a BCL2 Inhibitor

Management of Atrial Fibrillation in Patients With CLL on BTK Inhibitors

The Importance of Shared Decision-Making in the Frontline Setting